The stock of Sophiris Bio Inc (NASDAQ:SPHS) is a huge mover today! About 1.14 million shares traded hands or 57.17% up from the average. Sophiris Bio Inc (NASDAQ:SPHS) has risen 140.80% since April 27, 2016 and is uptrending. It has outperformed by 135.57% the S&P500.
The move comes after 7 months negative chart setup for the $90.62 million company. It was reported on Nov, 30 by Barchart.com. We have $2.59 PT which if reached, will make NASDAQ:SPHS worth $6.34M less.
Analysts await Sophiris Bio Inc (NASDAQ:SPHS) to report earnings on March, 22. They expect $-0.09 EPS, up 40.00% or $0.06 from last year’s $-0.15 per share. After $-0.15 actual EPS reported by Sophiris Bio Inc for the previous quarter, Wall Street now forecasts -40.00% EPS growth.
Sophiris Bio Inc (NASDAQ:SPHS) Ratings Coverage
Out of 3 analysts covering Sophiris Bio (NASDAQ:SPHS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Sophiris Bio has been the topic of 3 analyst reports since August 30, 2016 according to StockzIntelligence Inc. TH Capital initiated the stock with “Buy” rating in Thursday, September 15 report. The firm has “Overweight” rating given on Tuesday, August 30 by Piper Jaffray. The company was initiated on Thursday, September 15 by Roth Capital.
According to Zacks Investment Research, “Sophiris Bio Inc. operates as a biopharmaceutical company. The Company is developing a treatment for benign prostatic hyperplasia (BPH or enlarged prostate). It has operations based in San Diego. Sophiris Bio Inc. is based in Canada.”
Insitutional Activity: The institutional sentiment increased to 2.33 in 2016 Q2. Its up 1.56, from 0.77 in 2016Q1. The ratio increased, as 8 funds sold all Sophiris Bio Inc shares owned while 5 reduced positions. 5 funds bought stakes while 5 increased positions. They now own 1.50 million shares or 31.22% less from 2.18 million shares in 2016Q1.
Moreover, Fny Managed Accounts Limited Liability Corporation has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 7,556 shares. Royal Comml Bank Of Canada has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Citadel Advisors Ltd has 49,176 shares for 0% of their US portfolio. Palo Alto Invsts Ltd Liability has 0.08% invested in the company for 494,000 shares. Airain Limited has invested 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS). Bancshares Of America Corp De holds 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 1,222 shares. Jane Street Group Inc Ltd Company has 27,176 shares for 0% of their US portfolio. Moreover, Vanguard Grp Incorporated has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 331,000 shares. Retail Bank Of Montreal Can reported 1,632 shares or 0% of all its holdings. Moreover, Ladenburg Thalmann Fincl Svcs has 0% invested in Sophiris Bio Inc (NASDAQ:SPHS) for 600 shares. Rock Springs Mgmt Limited Partnership last reported 0.08% of its portfolio in the stock. The Germany-based Deutsche Bancorp Ag has invested 0% in Sophiris Bio Inc (NASDAQ:SPHS). Savings Bank Of Ny Mellon has 0% invested in the company for 18,866 shares. Kcg holds 0% of its portfolio in Sophiris Bio Inc (NASDAQ:SPHS) for 17,013 shares. Creative Planning owns 900 shares or 0% of their US portfolio.
More notable recent Sophiris Bio Inc (NASDAQ:SPHS) news were published by: Prnewswire.com which released: “Sophiris Bio to Present at 28th Annual Piper Jaffray Healthcare Conference” on November 22, 2016, also Prnewswire.com with their article: “Sophiris Bio Reports Third Quarter 2016 Financial Results and Key Business …” published on November 09, 2016, Prnewswire.com published: “Sophiris Bio Inc. Announces Closing of Public Offering of $5000000” on May 11, 2016. More interesting news about Sophiris Bio Inc (NASDAQ:SPHS) were released by: Prnewswire.com and their article: “Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as …” published on May 05, 2016 as well as Prnewswire.com‘s news article titled: “Sophiris Bio Inc. to Raise Approximately $5 Million Through At-the-Market Offering” with publication date: May 06, 2016.
SPHS Company Profile
Sophiris Bio Inc., incorporated on May 1, 2003, is a clinical-stage biopharmaceutical company. The Firm is focused on developing products for the treatment of urological diseases. The Firm is developing topsalysin (PRX302) as a treatment for the lower urinary tract symptoms of benign prostatic hyperplasia (BPH) commonly referred to as an enlarged prostate and as a treatment for localized low to intermediate risk prostate cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.